In Brief This Week: Abbott, Thermo Fisher Scientific, Danaher, Oncocyte, Biocartis, More
News items for the week of Feb. 20, 2023.
VolitionRx Prices $7.5M Public Offering
Volition intends to use the proceeds for research and continued product development and clinical studies, among other things.
In Brief This Week: Thermo Fisher Scientific, Leica Biosystems, Genetron, SomaLogic, More
News items for the week of Nov. 7, 2022.
VolitionRx, MD Anderson Cancer Center Partner to Study Cancer Patients With Sepsis
The study will use Volition's CE-marked Nu.Q NETs test to evaluate the role of neutrophil extracellular traps in cancer patients with sepsis.
VolitionRx Signs on Diagnostic Oncology CRO for Clinical Studies of Cancer, Sepsis Tests
DXOCRO will conduct large-scale clinical utility studies of Volition's Nu.Q NETs and Nu.Q Cancer tests at multiple sites in the US.
Jul 29, 2022
VolitionRx Prices $6M Public Offering
May 31, 2022
VolitionRx Gets CE Mark for NETosis Test
Feb 10, 2021
VolitionRx Prices $20M Public Offering
May 20, 2020
VolitionRx Prices $13.8M Stock Offering
Jul 10, 2019